Home/Filings/3/0001493152-18-001992
3//SEC Filing

ABV, LLC 3

Accession 0001493152-18-001992

CIK 0001686850other

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 7:17 PM ET

Size

22.6 KB

Accession

0001493152-18-001992

Insider Transaction Report

Form 3
Period: 2018-02-13
ABV, LLC
10% Owner
Holdings
  • Common Stock, par value $0.0001 per share

    (indirect: By Ascent Biomedical Ventures II, L.P.)
    1,447,129
  • Common Stock, par value $0.0001 per share

    (indirect: By Ascent Biomedical Ventures Synecor, L.P.)
    585,000
  • Series A Convertible Preferred Stock

    (indirect: By Ascent Biomedical Ventures II, L.P.)
    Exercise: $0.00Common Stock, par value $0.0001 per share (144,352 underlying)
  • Series A Convertible Preferred Stock

    (indirect: By Ascent Biomedical Ventures Synecor, L.P.)
    Exercise: $0.00Common Stock, par value $0.0001 per share (26,241 underlying)
  • Warrant (right to buy)

    (indirect: By Ascent Biomedical Ventures II, L.P.)
    Exercise: $5.00From: 2016-12-22Exp: 2021-12-22Common Stock, par value $0.0001 per share (156,734 underlying)
  • Warrant (right to buy)

    (indirect: By Ascent Biomedical Ventures Synecor, L.P.)
    Exercise: $5.00From: 2016-12-22Exp: 2021-12-22Common Stock, par value $0.0001 per share (27,433 underlying)
Footnotes (3)
  • [F1]The securities are directly held by Ascent Biomedical Ventures II, L.P ("ABV II"). Reporting Person serves as general partner to ABV II. Geoffrey W. Smith and Steve Hochberg are the managing members of Reporting Person. Mr. Smith and Mr. Hochberg jointly exercise sole dispositive and sole voting power over the shares owned by ABV II. Each of Mr. Smith, Mr. Hochberg and Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Smith, Mr. Hochberg or Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  • [F2]The securities are directly held by Ascent Biomedical Ventures Synecor, L.P ("ABV Synecor"). Reporting Person serves as general partner to ABV Synecor. Geoffrey W. Smith and Steve Hochberg are the managing members of Reporting Person. Mr. Smith and Mr. Hochberg jointly exercise sole dispositive and sole voting power over the shares owned by ABV Synecor. Each of Mr. Smith, Mr. Hochberg and Reporting Person disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Smith, Mr. Hochberg or Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  • [F3]Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) for a complete description of the conversion rights.

Issuer

Motus GI Holdings, Inc.

CIK 0001686850

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001599498

Filing Metadata

Form type
3
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 7:17 PM ET
Size
22.6 KB